Obesity and its associated complications comprise some of the world’s most pressing health issues.

We created Verdiva Bio to accelerate the development of differentiated medicines that address the significant unmet medical needs in this space.

Verdiva Bio is developing next-generation medicines with the goal of helping people living with obesity, cardiometabolic diseases, and related conditions achieve better health outcomes through more convenient and patient-friendly treatments.

Our pipeline is built around rationally engineered peptides designed for purpose. Our lead program, VRB-101, is an oral formulation of ecnoglutide, a cAMP-biased, GLP-1 peptide analog, which is currently in Phase 2 clinical development as a once-weekly treatment of obesity. Phase 1 results demonstrated promising efficacy and supported the potential for once-weekly oral dosing, enabled by a proprietary oral absorption enhancer, T2026, designed to support reliable delivery and scalable manufacturing.

Beyond our lead GLP-1 program, Verdiva is advancing a strategically focused portfolio of amylin-based therapies designed to support meaningful weight loss and healthier weight management. The portfolio spans oral and injectable candidates, while our active business development strategy seeks to add complementary assets that strengthen our long-term pipeline in obesity and metabolic disease.